Anthem Biosciences Limited, engaged in contract research, development, and manufacturing of complex APIs, biologics like probiotics and enzymes, peptides, biosimilars, plus biotech services for global pharma clients, jumped 2.13% to ₹710.75 after executing a First Amendment to convert an additional ₹275 crore loan into equity shares of its wholly-owned subsidiary Neoanthem Lifesciences.